Latest News
Opinion: Health care organizations screening for depression are skipping a critical question
The practice of omitting the ninth item on the PHQ-9 — the question about suicidality — because of liability concerns disregards the patient’s humanit...
STAT+: Trump administration leaves biotech investors more wary than ever of funding mRNA vaccines
The Trump administration’s decision to halt nearly $500 million for mRNA vaccine research has made investors more hesitant to back biotechs in this sp...
STAT+: Pharmalittle: We’re reading about FDA OK for a lung disease drug, pharma sales in China, and more
Insmed received FDA clearance for the first treatment for a chronic lung disease, opening the way to a potential multibillion-dollar product
Life expectancy is lower in the U.S. For kids, too.
And more health news updates.
STAT+: Stoke Therapeutics release new data on Dravet syndrome drug
And other biotech news of the day, brought to you by The Readout.
STAT+: OpenAI can’t have it both ways on GPT-5 and health
Why OpenAI may run into trouble with the FDA for promoting GPT-5's health advice with little supporting evidence
STAT+: Duke scientists seemed to have developed a ‘Holy Grail’ of cancer treatment. Then the truth came out
A fraudulent cancer breakthrough, a test for the future president of MIT, and a new age of doubt in science.
Deconstructing RFK Jr.’s explanation for the cancellation of mRNA vaccine contracts
In a new episode of the video series STATus Report, a closer look at the reasons health secretary RFK Jr. cited for canceling contracts on mRNA vaccin...
STAT+: Drugmakers form new group to lobby on impact of Medicare drug price negotiations
Drug companies have formed a new group to present lawmakers with research on what the industry sees as the negative impacts of Medicare drug price neg...
Another explanation for canceled mRNA contracts
And other health news stories of the day.
Opinion: Health care organizations screening for depression are skipping a critical question
STAT+: Trump administration leaves biotech investors more wary than ever of funding mRNA vaccines
STAT+: Pharmalittle: We’re reading about FDA OK for a lung disease drug, pharma sales in China, and more
Life expectancy is lower in the U.S. For kids, too.
STAT+: Stoke Therapeutics release new data on Dravet syndrome drug
STAT+: OpenAI can’t have it both ways on GPT-5 and health
STAT+: Duke scientists seemed to have developed a ‘Holy Grail’ of cancer treatment. Then the truth came out
Deconstructing RFK Jr.’s explanation for the cancellation of mRNA vaccine contracts
STAT+: Drugmakers form new group to lobby on impact of Medicare drug price negotiations
Another explanation for canceled mRNA contracts
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago